lenalidomide has been researched along with Graft-Versus-Host Disease in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.00) | 29.6817 |
| 2010's | 13 (65.00) | 24.3611 |
| 2020's | 6 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abedi, M; Hoeg, R; Krishnan, R; Pham, B; Richman, C; Tuscano, J | 1 |
| Chandar, R; Meena, S; Raj, R; Ramakrishnan, B; Uppuluri, R; Varla, H; Vellaichamy Swaminathan, V | 1 |
| Ito, T; Nasa, Y; Nomura, S; Satake, A; Tsubokura, Y; Tsuji, R; Yoshimura, H | 1 |
| Aoki, J; Fukuda, T; Inamoto, Y; Ito, A; Kim, SW; Takeda, W; Tanaka, T; Watanabe, M | 1 |
| Cadeddu, RP; Christopeit, M; Drusenheimer, N; Esseling, E; Germing, U; Haas, R; Holtick, U; Jäger, P; Klein, S; Kobbe, G; Kröger, N; Mikesch, JH; Rautenberg, C; Scheid, C; Schroeder, T; Stelljes, M; Trenschel, R | 1 |
| Ginn, M; Strouse, C; Struble, E | 1 |
| Ahmed, S; Alousi, AM; Bassett, RL; Bueso-Ramos, CE; Ciurea, SO; Gulbis, AM; Jabbour, EJ; Khouri, IF; Khouri, MR; Korbling, M; Ledesma, C; Marin, D; Patel, KK; Popat, UR; Samuels, BI; Turturro, F | 1 |
| Bolwell, BJ; Corrigan, D; Dean, R; Gerds, A; Hamilton, BK; Hill, BT; Jagadeesh, D; Kalaycio, M; Khouri, J; Liu, HD; Majhail, NS; Pohlman, B; Reu, F; Sobecks, R | 1 |
| Cosiglio, FJ; Ordi-Ros, J | 1 |
| Abe, Y; Ikeda, M; Meshitsuka, S; Miyazaki, K; Shingaki, S; Suzuki, K; Tsukada, N; Yoshiki, Y | 1 |
| Chaturvedi, S; Mohty, M; Nagler, A; Neff, A; Savani, BN; Savani, U | 1 |
| Izzedine, H; Kheder El-Fekih, R | 1 |
| Aarts, T; Emmelot, M; Lokhorst, HM; Minnema, MC; Mutis, T; van der Veer, MS | 1 |
| Asch, J; Ford, CD; Konopa, K; Petersen, FB | 1 |
| Arfons, LM; Ataergin, SA; Barr, PM; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Kaplan, D; Kaye, NM; Kindwall-Keller, TL; Laughlin, MJ; Lazarus, HM; Liu, F; Sommers, SR | 1 |
| Gahrton, G | 1 |
| Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S | 1 |
| Blaise, D; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Duran, S; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Ladaique, P; Lemarie, C; Oudin, C; Schiano De Colella, JM; Stoppa, AM | 1 |
| Atanackovic, D; Ayuk, F; Dreger, P; Hegenbart, U; Heinzelmann, M; Hildebrandt, Y; Kröger, N; Schönland, S; Stübig, T; Wolschke, C; Zander, A | 1 |
| Bachy, E; Bourhis, JH; Brebion, A; Coman, T; François, S; Hermine, O; Huynh, A; Lapusan, S; Lioure, B; Maury, S; Michallet, M; Milpied, N; Mohty, M; Rubio, MT; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I | 1 |
3 review(s) available for lenalidomide and Graft-Versus-Host Disease
| Article | Year |
|---|---|
[Current therapeutic indications of thalidomide and lenalidomide].
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Antineoplastic Agents; Collagen Diseases; Endocrine System Diseases; Gastrointestinal Diseases; Graft vs Host Disease; Hematologic Diseases; Humans; Immunologic Factors; Inflammation; Lenalidomide; Neoplasms; Neoplasms, Second Primary; Peripheral Nervous System Diseases; Safety-Based Drug Withdrawals; Skin Diseases; Thalidomide; Thrombophilia; Vasculitis | 2014 |
Venous thromboembolism in hematopoietic stem cell transplant recipients.
Topics: Allografts; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Postoperative Complications; Thalidomide; Venous Thromboembolism | 2016 |
[Lenalidomide nephrotoxicity].
Topics: Graft vs Host Disease; Humans; Immunologic Factors; Kidney; Kidney Tubules; Lenalidomide; Necrosis; Nephritis, Interstitial; Prevalence; Renal Insufficiency; Thalidomide | 2016 |
6 trial(s) available for lenalidomide and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transplantation, Homologous | 2021 |
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.
Topics: Acute Disease; Aged; Allografts; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Transfusion; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; Thalidomide | 2017 |
Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Forkhead Transcription Factors; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphocyte Count; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; T-Lymphocytes, Regulatory; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2009 |
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Drug Eruptions; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Lymphocyte Count; Male; Melphalan; Middle Aged; Multiple Myeloma; Mycophenolic Acid; Prospective Studies; Remission Induction; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 2011 |
Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunotherapy, Adoptive; Lenalidomide; Living Donors; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Homologous | 2012 |
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Topics: Adult; Aged; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Immunologic; Female; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Lymphocyte Count; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Thalidomide; Transplantation Conditioning; Transplantation, Homologous | 2013 |
11 other study(ies) available for lenalidomide and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Post-transplant strategies to improve relapse-free survival in childhood leukemia: Whole blood donor lymphocyte infusions and lenalidomide for inducing graft-versus-leukemia effect.
Topics: Blood Donors; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Lymphocytes; Recurrence; Retrospective Studies | 2022 |
Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract.
Topics: Cell Movement; Gastrointestinal Tract; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Transplantation, Homologous | 2022 |
Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation.
Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Recurrence; Retrospective Studies | 2023 |
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
Topics: Adult; Azacitidine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Transfusion; Myelodysplastic Syndromes; Recurrence; T-Lymphocytes; Transplantation, Homologous | 2023 |
Acute auto-aggression syndrome following autologous hematopoietic stem cell transplant and lenalidomide for multiple myeloma.
Topics: Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous | 2023 |
Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Premedication; Transplantation, Homologous | 2019 |
[Graft-versus-host disease associated with lenalidomide maintenance after allogeneic transplantation for relapsed/refractory multiple myeloma].
Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Transplantation, Homologous | 2015 |
CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Recurrence; Thalidomide | 2010 |
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Boronic Acids; Bortezomib; Case-Control Studies; Cytokine Receptor gp130; Female; GATA2 Transcription Factor; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Receptors, CXCR4; T-Lymphocyte Subsets; Thalidomide; Transplantation, Autologous | 2011 |
Allogeneic transplantation in multiple myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Mice; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2011 |
Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy.
Topics: Adult; Antineoplastic Agents; Female; France; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2013 |